Back to search

University of Thessaly (UTH)

Η φυσική ιστορία της χρόνιας λοίμωξης από τον ιό της ηπατίτιδας Β' σε ασθενείς της Κεντρικής Ελλάδας

Abstract

dc:description

Introduction/Aim. Hepatitis B virus (HBV) infection nowadays remains a serious public health problem with changing epidemiology due to various factors, including vaccination programs and population migration. The aim of the present study was to assess the epidemiological characteristics and the evolution of the disease in Central Greece. Patients and Methods. 1910 consecutive patients with chronic hepatitis B, who were followed for the last 16 years (1999-2016) at the Department of Medicine and Research Laboratory of Internal Medicine, University of Thessaly, were included. We determine the risk and factors associated with the progression of the disease to cirrhosis, decompensation, hepatocellular carcinoma (HCC), and liver-related death. Epidemiological changes have been studied over the course of recent years. Finally, subanalysis was performed in a subgroup of 255 patients treated with tenofovir (TDF) or entecavir (ETV). Results. 1161 (60.8%) were males and 749 (39.2%) were women. The mean age ± SD at the baseline visit was 50.1 ± 15.8 years. Moderate alcohol use or abuse was reported from 622 (32.6%) patients. The body mass index (BMI) of patients was 26.5 ± 3.4 kg/m2, with 545 (28.5%) having a BMI >25 kg/m2. The most common sources of infection were vertical transmission or intrafamilial transmission during early childhood (1085, 56.8%) and traditional practices (328, 17.2%). The majority of patients, 1731 (90.6%) were of Greek origin, while 153 (8%) were of Albanian origin. Regarding the mode of presentation, 23 (1.2%) presented with acute hepatitis and in 84 (4.4%) patients the disease was diagnosed due to symptomatic chronic liver disease. The remaining patients were asymptomatic.In regards to the clinical phase of the infection at the first assessment, 1314 (68.8%) patients were characterized with chronic infection (inactive carriers), 415 (21.7%) patients were characterized with chronic hepatitis and 105 (5.5%) were already cirrhotic (compensated stage), 11 (0.6%) decompensated, and 65 (3.4%) with HCC. Several areas with increased rates of patients with chronic hepatitis B were detected. Non-cirrhotic patients with chronic hepatitis compared with those with chronic infection (inactive carriers) were more likely to be male (P<0.001), with a higher BMI (P=0.003) and history of alcohol consumption (P<0.001). Patients with cirrhosis ± HCC compared to non-cirrhotic with chronic hepatitis B were more likely to be male (P<0.001), older (P<0.001), with longer duration of infection (P<0.001) and reported more frequent alcohol consumption (P<0.001).Patients evaluated for the first time in our centre during ‘2011-2016’ were older (P<0.001), with longer duration of infection (P<0.001) and lower BMI (P<0.05) compared to patients from the period ‘1999-2010’. It was also more frequent during the period 2011-2016 to attend patients with foreign nationality (P<0.001). There was statistical trend for patients with a more advanced disease stage during the second period (P=0.085). Of the 415 non-cirrhotic patients with chronic hepatitis B at baseline, 51 (12.3%) developed cirrhosis during follow-up. The cumulative incidence of cirrhosis in the 1st, 5th, 10th and 15th year was 0.2%, 8.3%, 15.3% and 17.5%, respectively. Negative prognostic factors for cirrhosis development were γGT (P<0.02) and virological breakthrough during treatment (P<0.01). Decompensation during follow up was observed in 34/156 (21.8%) cirrhotic patients. The cumulative incidence of decompensation in the 1st, 5th, 10th and 15th year was 3.2%, 12.8%, 24.6% and 28.2%, respectively. Low levels of albumin were found to be independent prognostic factor (P<0.02), with a trend towards alcohol consumption (P=0.05).HCC was developed in 64/531 (12.1%) with chronic hepatitis B with or without cirrhosis at baseline with a cumulative incidence on the 1st, 5th, 10th and 15th year of 1.1%, 7.7%, 13.8% and 15.9%, respectively. The presence of cirrhosis (P<0.001) and virologic breakthrough during treatment (P<0.05) were independent negative predictive factors for HCC.Liver-related death occurred in 47/531 (8.9%) patients with chronic hepatitis B with or without cirrhosis at baseline. The cumulative incidence of liver related death in the 1st, 5th, 10th and 15th year was 1.1%, 5.8%, 9.9% and 11.4%, respectively. The incidence of cirrhosis (P<0.001), duration of infection (P<0.05) and low levels of albumin (P=0.001) were associated with liver-related death.Patients starting followed at our center from 2011 onwards had lower rates of virological breakthrough (P<0.001) and biochemical relapse (P<0.001) during treatment. Also, fewer patients progressed to cirrhosis (P <0.02) and HCC (P<0.04). Subanalysis in 255 patients treated with TDF or ETV showed that HCC developed in 18 (7.1%) patients during follow up. The cumulative HCC incidence was 0.4%, 2.1%, 4.4%, 9.1%, 10.2% at the 2nd, 3rd, 5th, 7th and 10th year after initiation of ETV/TDF, respectively. Increased age (P<0.001) and alcohol consumption (P<0.02) correlated negatively with HCC development. The AUROC (95% CI) of the PAGE-B risk score for HCC prognosis was 0.709 (0.605-0.813), P<0.01 in all patients, 0.758 (0.623-0.892), P=0.006 in non-cirrhotic, and 0.525 (0.324-0.725), P = 0.825 in cirrhotic. No patient with a PAGE-B score less than 10 developed cancer (negative predictive value 100%). In all patients, the annual HCC incidence was 0.86% within the first five years and 0.54% after the first 5 years of treatment with ETV/TDF. During follow-up, 221/255 (86.7%) patients remained alive till their last follow-up, 9/225 (3.5%) died due to liver disease and 25 (9.8%) died due to non-hepatic disease. The overall survival in the 1st, 5th and 8th year was 100%, 90.3% and 83.9%, respectively, and survival related to liver disease was 100%, 97.8% and 94.3%. Alcohol abuse in the past or at baseline ETV/TDF (P=0.05) and HCC development (P<0.001) were associated with liver-related mortality. Conclusions. Chronic hepatitis B continues to be a major public health problem in the wider region of Central Greece, with areas of high prevalence still preserved. Despite the implementation of prevention and early detection strategies, there is an increase of cirrhotic patients. Alcohol consumption continues to be an aggravating factor.The recent effective and high-barrier to resistance antiviral drugs (ETV / TDF) appear to improve the natural history of the disease by reducing the incidence of HCC after their first five years of administration and improving the survival of patients with chronic hepatitis B.However, it should be kept in mind that HCC can be developed even in patients treated effectively, and therefore a careful assessment of the risk of developing HCC and close surveillance are necessary. PAGE-B risk score can help to predict HCC development in non-cirrhotic patients with chronic hepatitis B and due to its simplicity, it can be used in everyday clinical practice.

Degree

thesis:*
Grantor dc:publisher
University of Thessaly (UTH)
Year dc:date
2018

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Galanis, Konstantinos
  • Γαλάνης, Κωνσταντίνος

Subjects

dc:subject × 7

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/44471

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Galanis, Konstantinos; Γαλάνης, Κωνσταντίνος. Η φυσική ιστορία της χρόνιας λοίμωξης από τον ιό της ηπατίτιδας Β' σε ασθενείς της Κεντρικής Ελλάδας. University of Thessaly (UTH), 2018. http://hdl.handle.net/10442/hedi/44471